Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) FCF Margin (2016 - 2025)

Historic FCF Margin for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to 63.62%.

  • Enanta Pharmaceuticals' FCF Margin rose 870200.0% to 63.62% in Q4 2025 from the same period last year, while for Dec 2025 it was 27.57%, marking a year-over-year increase of 1173200.0%. This contributed to the annual value of 49.24% for FY2025, which is 937500.0% up from last year.
  • As of Q4 2025, Enanta Pharmaceuticals' FCF Margin stood at 63.62%, which was up 870200.0% from 52.54% recorded in Q3 2025.
  • In the past 5 years, Enanta Pharmaceuticals' FCF Margin ranged from a high of 94.74% in Q2 2025 and a low of 181.45% during Q2 2023
  • For the 5-year period, Enanta Pharmaceuticals' FCF Margin averaged around 104.39%, with its median value being 119.04% (2023).
  • Its FCF Margin has fluctuated over the past 5 years, first plummeted by -1179300bps in 2022, then surged by 2114900bps in 2025.
  • Enanta Pharmaceuticals' FCF Margin (Quarter) stood at 49.31% in 2021, then crashed by -234bps to 164.5% in 2022, then grew by 13bps to 143.17% in 2023, then fell by -5bps to 150.63% in 2024, then skyrocketed by 58bps to 63.62% in 2025.
  • Its FCF Margin stands at 63.62% for Q4 2025, versus 52.54% for Q3 2025 and 94.74% for Q2 2025.